Page 1

BIOARCTIC INTERIM REPORT New data continues to strengthen lecanemab January - March 2021 EVENTS DURING THE FIRST QUARTER 2021 • BioArctic presented findings at the AD / PD conference suggesting that lecanemab could be developed into a disease modifying treatment for individuals with Down's syndrome with dementia . New preliminary results presented from the ongoing open - label extension of the Phase 2b study in early Alzheimer's disease continued to support the effect of the drug candidate lecanemab on brain amyloid levels . EVENTS AFTER THE PERIOD • Lecanemab Phase 2b study results in early Alzheimer's disease published in peer - reviewed journal , Alzheimer's Research and Therapy , and lecanemab confirmatory Phase 3 Clarity AD clinical trial completed enrollment with 1,795 patients . FINANCIAL SUMMARY JANUARY - MARCH 2021 • Net revenues for the period amounted to MSEK 7.2 ( 36.4 ) • Operating profit amounted to MSEK -29.1 ( 3.8 ) • Profit for the period amounted to MSEK -29.1 ( 3.6 ) and earnings per share were SEK -0.33 ( 0.04 ) Cash flow from operating activities amounted to MSEK -37.5 ( -36.3 ) • Cash and cash equivalents at the end of the period amounted to MSEK 960.5 ( 1,077.3 ) KEY FINANCIAL PERFORMANCE INDICATORS Q1 Jan - Dec MSEK Net revenues Other operating income Operating profit / loss Operating margin , % Profit / loss for the period 2021 2020 2020 7.2 36.4 62.3 1.7 3.4 3.6 -29.1 3.8 -85.0 neg 10.4 neg -29.1 3.6 -68.5 Earnings per share before dilution , SEK -0.33 0.04 -0.78 Earnings per share after dilution , SEK -0.33 0.04 -0.78 Equity per share , SEK 9.98 11.11 10.30 Cash flow from operating activities -37.5 -36.3 -92.3 Cash flow from operating activities per share , SEK -0.43 -0.41 -1.05 Equity / assets ratio , % 87.3 85.6 86.4 Return on equity , % -3.26 0.36 -7.28 Share price at the end of the period , SEK 91.00 61.50 95.40 Unless otherwise stated , this Interim report refers to the Group . Figures in parentheses refer to the corresponding period last year . The amounts stated are rounded , which sometimes leads to some totals not being exact . Q1 January - March 2021 1